Avadel Pharmaceuticals plc

AVDL

IE00BDGMC594

Pharmaceuticals

Delayed Nasdaq Other stock markets 04:00:00 2026-02-11 pm EST			5-day change	1st Jan Change
21.64 ^USD	+0.05%		-.--%	+0.42%

Mar. 02	Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026	CI
Feb. 12	Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market	RE

Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from S&P Global BMI Index

Published on 02/11/2026 at 07:23 pm EST

S&P Capital IQ

AVADEL PHARMACEUTICALS PLC

+0.05%

S&P GLOBAL, INC.

-1.81%

Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from S&P Global BMI Index

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	AVADEL PHARMACEUTICALS PLC	21.64USD	+0.05%	-.--%	2.12B
	S&P GLOBAL, INC.	427.57USD	-1.81%	-3.68%	130B

Latest news about Avadel Pharmaceuticals plc

Mar. 02	Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026	CI
Feb. 12	Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market	RE
Feb. 12	Alkermes plc completed the acquisition of Avadel Pharmaceuticals plc.	CI
Feb. 12	Alkermes Completes Acquisition of Avadel	MT
Feb. 12	Avadel Pharmaceuticals plc Announces Board of Director Changes	CI
Feb. 11	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from S&P Global BMI Index	CI
Feb. 11	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from S&P Pharmaceuticals Select Industry Index	CI
Feb. 11	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from S&P TMI Index	CI
Feb. 11	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from NASDAQ Composite Index	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell Small Cap Comp Growth Benchmark	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell 3000E Growth Benchmark	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell 3000 Growth Benchmark	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell 2500 Growth Benchmark	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell 2000 Growth Benchmark	CI
Feb. 10	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) dropped from Russell 2500 Growth-Dynamic Index	CI

Chart Avadel Pharmaceuticals plc

Duration

Period

AVDL: Dynamic Chart

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Employees

188

Sector

Pharmaceuticals

More about the company